Anti-PD1-induced psoriasis: a study of 21 patients

Journal of the European Academy of Dermatology and Venereology

Volumn 31, Issue 5, 2017, Pages e254-e257

  Bonigen, J ^a   Raynaud Donzel, C ^a   Hureaux, J ^b   Kramkimel, N ^c   Blom, A ^d   Jeudy, G ^e   Breton, A L ^f   Hubiche, T ^g   Bedane, C ^h   Legoupil, D ⁱ   Pham Ledard, A ^j   Charles, J ^k   Perol M ^l   Gerard E ^j   Combemale, P ^l   Bonnet, D ^d   Sigal, M L ^a   Mahe E ^a  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c Assistance Publique Hôpitaux de Paris ^*  (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e HÔPITAL DU BOCAGE   (France)

^f HOSPICES CIVILS DE LYON   (France)

^g Centre Hospitalier Intercommunal de Frejus Saint Raphael   (France)

^h LIMOGES UNIVERSITY HOSPITAL   (France)

ⁱ BREST UNIVERSITY HOSPITAL   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k GRENOBLE UNIVERSITY HOSPITAL   (France)

^l CENTRE LÉON BÉRARD   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; ETRETIN; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

HUMAN; LETTER; MEDLINE; MELANOMA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT WITHDRAWAL; ADAPTIVE IMMUNITY; AGED; DISEASE EXACERBATION; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; VERY ELDERLY;

ADAPTIVE IMMUNITY; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; PSORIASIS;

EID: 84998706924     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.14011     Document Type: Letter

References (8)

1. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.
2. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of Anti-PD1 antibody in Cancer. N Engl J Med 2012; 366: 2443–2454.
3. Robert C, Ribas A, Wolchok JD. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014; 384: 1109–1117.
4. Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park) 2015; 29: 375–385.
5. Ohtsuka M, Miura T, Mori T et al. Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatol 2015; 151: 797–799.
6. Matsumura N, Ohtsuka M, Kikuchi N et al. Exacerbation of psoriasis during nivolumab therapy for metastatic melanoma. Acta Derm Venereol 2016; 96: 259–260.
7. Kato Y, Otsuka A, Miyachi Y et al. Exacerbation of psoriasis vulgaris during nivolumab for oral mucosal melanoma. J Eur Acad Dermatol Venereol 2016; 30: e89–e91.
8. Sahuquillo-Torralba A, Ballester-Sánchez R, Pujol-Marco C et al. Pembrolizumab, un nuevo fármaco capaz de inducir un brote psoriasis. Actas Dermosifiliogr 2016; 107: 264–266.